AN2 Therapeutics (ANTX) Equity Ratio (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Equity Ratio data on file, last reported at 0.93 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.93, up 3.66% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.93 (up 3.66% YoY), and the FY2025 annual result was 0.86, down 3.64% from the prior year.
• Equity Ratio climbed to 0.93 in Q1 2026 per ANTX's latest filing, from 0.86 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.97 in Q2 2022 and troughed at 0.86 in Q4 2025.
• A 5-year average of 0.91 and a median of 0.91 in 2023 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio jumped 228.11% in 2022, then declined 8.1% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.93 in 2022, then dropped by 3.35% to 0.9 in 2023, then retreated by 1.11% to 0.89 in 2024, then fell by 3.64% to 0.86 in 2025, then increased by 9.11% to 0.93 in 2026.
• Business Quant data shows ANTX's Equity Ratio at 0.93 in Q1 2026, 0.86 in Q4 2025, and 0.9 in Q3 2025.